Sex-specific Prediction of Cardiogenic Shock After Acute Coronary Syndromes: The SEX-SHOCK Score.

C-reactive protein LVEF acute coronary syndromes atherosclerosis cardiogenic shock gender medicine inflammation machine learning multilayer perceptron percutaneous coronary intervention personalized risk prediction precision medicine random forest

Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
01 Sep 2024
Historique:
received: 10 07 2024
revised: 05 08 2024
accepted: 30 08 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 1 9 2024
Statut: aheadofprint

Résumé

and aims: Cardiogenic shock (CS) remains the primary cause of in-hospital death after acute coronary syndromes (ACS), with its plateauing mortality rates approaching 50%. To test novel interventions, personalized risk prediction is essential. The ORBI (Observatoire Régional Breton sur l'Infarctus) score represents the first-of-its-kind risk score to predict in-hospital CS in ACS patients undergoing percutaneous coronary intervention (PCI). However, its sex-specific performance remains unknown, and refined risk prediction strategies are warranted. This multinational study included a total of 53 537 ACS patients without CS on admission undergoing PCI. Following sex-specific evaluation of ORBI, regression and machine-learning models were used for variable selection and risk prediction. By combining best-performing models with highest-ranked predictors, SEX-SHOCK was developed, and internally and externally validated. The ORBI score showed lower discriminative performance for the prediction of CS in females than males in Swiss (AUC [95% CI]: 0.78 [0.76-0.81] vs. 0.81 [0.79-0.83]; p=0.048) and French ACS patients (0.77 [0.74-0.81] vs. 0.84 [0.81-0.86]; p=0.002). The newly developed SEX-SHOCK score, now incorporating ST-segment elevation, creatinine, C-reactive protein, and left ventricular ejection fraction, outperformed ORBI in both sexes (females: 0.81 [0.78-0.83]; males: 0.83 [0.82-0.85]; p<0.001), which prevailed following internal and external validation in RICO (females: 0.82 [0.79-0.85]; males: 0.88 [0.86-0.89]; p<0.001) and SPUM-ACS (females: 0.83 [0.77-0.90], p=0.004; males: 0.83 [0.80-0.87], p=0.001). The ORBI score showed modest sex-specific performance. The novel SEX-SHOCK score provides superior performance in females and males across the entire spectrum of ACS, thus providing a basis for future interventional trials and contemporary ACS management.

Sections du résumé

BACKGROUND BACKGROUND
and aims: Cardiogenic shock (CS) remains the primary cause of in-hospital death after acute coronary syndromes (ACS), with its plateauing mortality rates approaching 50%. To test novel interventions, personalized risk prediction is essential. The ORBI (Observatoire Régional Breton sur l'Infarctus) score represents the first-of-its-kind risk score to predict in-hospital CS in ACS patients undergoing percutaneous coronary intervention (PCI). However, its sex-specific performance remains unknown, and refined risk prediction strategies are warranted.
METHODS METHODS
This multinational study included a total of 53 537 ACS patients without CS on admission undergoing PCI. Following sex-specific evaluation of ORBI, regression and machine-learning models were used for variable selection and risk prediction. By combining best-performing models with highest-ranked predictors, SEX-SHOCK was developed, and internally and externally validated.
RESULTS RESULTS
The ORBI score showed lower discriminative performance for the prediction of CS in females than males in Swiss (AUC [95% CI]: 0.78 [0.76-0.81] vs. 0.81 [0.79-0.83]; p=0.048) and French ACS patients (0.77 [0.74-0.81] vs. 0.84 [0.81-0.86]; p=0.002). The newly developed SEX-SHOCK score, now incorporating ST-segment elevation, creatinine, C-reactive protein, and left ventricular ejection fraction, outperformed ORBI in both sexes (females: 0.81 [0.78-0.83]; males: 0.83 [0.82-0.85]; p<0.001), which prevailed following internal and external validation in RICO (females: 0.82 [0.79-0.85]; males: 0.88 [0.86-0.89]; p<0.001) and SPUM-ACS (females: 0.83 [0.77-0.90], p=0.004; males: 0.83 [0.80-0.87], p=0.001).
CONCLUSIONS CONCLUSIONS
The ORBI score showed modest sex-specific performance. The novel SEX-SHOCK score provides superior performance in females and males across the entire spectrum of ACS, thus providing a basis for future interventional trials and contemporary ACS management.

Identifiants

pubmed: 39217456
pii: 7745653
doi: 10.1093/eurheartj/ehae593
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Yifan Wang (Y)

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.

Marianne Zeller (M)

Department of Cardiology, CHU Dijon Bourgogne, Dijon, France.
Physiolopathologie et Epidémiologie Cérébro-Cardiovasculaire (PEC2), EA 7460, Univ Bourgogne, Dijon, France.

Vincent Auffret (V)

Université de Rennes 1, CHU Rennes Service de Cardiologie, Inserm LTSI U1099, Rennes, France.

Georgios Georgiopoulos (G)

Department of Physiology, School of Medicine, University of Patras, Greece.
Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
School of Biomedical Engineering and Imaging Sciences, King's College London, UK.

Lorenz Räber (L)

Department of Cardiology, Swiss Heart Center, Inselspital Bern, Switzerland.

Marco Roffi (M)

Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland.

Christian Templin (C)

Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
University Heart Center, Department of Cardiology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland.

Olivier Muller (O)

Department of Cardiology, Lausanne University Hospital-CHUV, Lausanne, Switzerland.

Luca Liberale (L)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.

Stefano Ministrini (S)

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.

Kimon Stamatelopoulos (K)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Konstantinos Stellos (K)

Department of Cardiovascular Research, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Helmholtz Institute for Translational AngioCardioScience (HI-TAC)-a branch of the MDC at Heidelberg University, Heidelberg, Germany.
Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Giovanni G Camici (GG)

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.

Fabrizio Montecucco (F)

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, Genoa, Italy.

Hans Rickli (H)

Cardiology Department, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Maud Maza (M)

Department of Cardiology, CHU Dijon Bourgogne, Dijon, France.

Dragana Radovanovic (D)

AMIS Plus Data Centre, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Yves Cottin (Y)

Department of Cardiology, CHU Dijon Bourgogne, Dijon, France.

Frédéric Chague (F)

Department of Cardiology, CHU Dijon Bourgogne, Dijon, France.

David Niederseer (D)

Hochgebirgsklinik, Medicine Campus Davos, Herman-Burchard-Strasse 1, 7270, Davos, Switzerland.
Christine Kühne Center for Allergy Research and Education (CK-CARE), Medicine Campus Davos, Davos, Switzerland.

Thomas F Lüscher (TF)

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Royal Brompton and Harefield Hospitals and National Heart and Lung Institute, Imperial College, London, UK.

Simon Kraler (S)

Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland.

Classifications MeSH